-
Sort By
-
Newest
-
Newest
-
Oldest
Vaccine trial restart boosts markets, ASX strength to continue, COVID-19 impacting Macquarie Group A positive lead from Wall Street and news that AstraZeneca plc (NYSE:AZN) had resumed their vaccine trial sent the ASX 200 (ASX:XJO) 0.7% higher on Monday. Positive news on the vaccine front support the energy and industrial sectors amid hope of a…
It was a mixed day for the market, the ASX 200 (ASX:XJO) finished 0.2% higher despite trading up as much as 0.8% during the day.